Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bivalent RSV+HMPV protein vaccine · RPF08203

Vaccine (Recombinant protein vaccine) · Immune activation · developed by Sanofi

Phase 2 Most advanced trial
SNY Developer

What is Bivalent RSV+HMPV protein vaccine?

Bivalent RSV+HMPV protein vaccine (RPF08203) is a protein-based vaccine intended to induce immunity against respiratory syncytial virus and human metapneumovirus. It is studied in healthy volunteers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RPF08203
Drug type
Vaccine (Recombinant protein vaccine)
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

Conditions studied

Healthy VolunteersHuman MetapneumovirusRespiratory Syncytial Virus

More from Sanofi

Follow SNY, the company behind Bivalent RSV+HMPV protein vaccine

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.